Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Granted Patent for CEfrag™ Drug Discovery Platform

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
CEfrag™ platform uses capillary electrophoresis to identify fragment compounds.

Selcia Limited has been granted a UK patent for the technology platform underpinning the company’s CEfrag™ drug screening service.

Titled “Capillary electrophoresis method for assessing the binding of chemical compounds to biological targets”, the patent relates to the screening of compound libraries against specific targets, in particular screening for weak-binding ligands.

Numbered GB 2481168, the patent was filed 20 September 2010 and granted 27 June 2012.

The patenting of Selcia’s CEfrag technology is the culmination of a three year plan by Selcia to build a fully integrated drug discovery division alongside its existing 14C radiochemistry service.

The newly patented technology was first unveiled by Selcia following the acquisition of IP and expertise from Cetek Corporation in 2009.

Further technical development of the fragment screening platform resulted in the launch of CEfrag the following year with a fragment library of 1,500 compounds.

CEfrag has generated a great deal of interest amongst pharmaceutical and biotech organizations and this has already resulted in a number of collaborations including a recent deal with Heptares, a UK-based biotech company that discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors) The goal of this collaboration was to identify fragment ligands that specifically bind to a Heptares GPCR drug target.

Selcia’s CEfrag™ platform uses capillary electrophoresis to identify fragment compounds that selectively bind to drug targets.

A significant advantage of this approach is that all reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate.

The technology can be used to detect fragment/target interactions across a wide range of target classes including “challenging” targets such as protein-protein interactions.

The technology can also be used to screen natural extracts for novel druggable natural compound starting points for drug discovery programmes, an area in which Selcia specializes.

Simon Bury, Business Development Director - Discovery, Selcia, comments: “The CEfrag drug screening platform has already shown itself to be a novel, scientifically robust approach to drug discovery. By patenting the technology we have demonstrated our strong intent to build a differentiated technology platform that will sit at the heart of Selcia’s integrated drug discovery service capabilities”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Appoints New Director of Discovery
Appointment of John Davis to the role of Director of Discovery.
Wednesday, October 09, 2013
Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
Partnership to utilize Selcia’s CEfrag™ capillary electrophoresis fragment screening technology.
Thursday, April 19, 2012
Scientific News
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!